Target Synonym: CLDN18, Claudin 18, UNQ778/PRO1572, Pulmonary Associated Protein J, Surfactant Associated 5, and Surfactant Associated JClaudin-18, SFTPJ, Claudin 18. ...

Claudin18.2, a known subtype of Claudin18 ... gastric cancer, ovarian cancer, lung cancer, cholangiocarcinoma, among others. As a result, it has become a popular target for immunotherapy, such ...

NEW YORK – Carsgen Therapeutics on Monday said it plans to seek approval in China for its autologous CAR T-cell therapy satricabtagene autoleucel (satri-cel) in previously treated patients with ...

This study is an open-label, multicenter clinical trial evaluating the safety and efficacy of satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell product candidate against ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

SHANGHAI, Dec. 30, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic ...

This study is an open-label, multicenter clinical trial evaluating the safety and efficacy of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against ...

Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2 ...

About Satri-cel Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of ...